IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.72▲ 0.87% USD/MXN18.61▲ 0.56% USD/CLP1,001▲ 0.63% USD/COP3,314▲ 0.34% USD/PEN3.40▼ 0.08% USD/ARS1,547▲ 0.21% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 — 0.00% USD/DOP60.63▲ 0.07% USD/CRC 442.74 — 0.00% USD/GTQ7.64▲ 3.24% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69— 0.00% USD/TTD6.75▲ 2.58% EUR/BRL6.30▲ 0.77% BRENT 94.43 ▼ 1.47% WTI 87.68 ▼ 0.99% IRON ORE 161.91 — — COPPER 6.05 ▼ 0.52% GOLD 3,874 ▼ 0.32% SILVER 47.30 ▼ 3.54% SOY 1,229 ▼ 1.13% CORN 445.00 ▼ 0.11% WHEAT 590.25 ▼ 0.51% COFFEE 274.75 ▼ 1.40% SUGAR 18.33 ▼ 0.43% ORANGE JUICE 136.85 ▼ 2.91% COTTON 81.51 ▲ 3.47% COCOA 5,254 ▲ 2.64% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.73 ▲ 1.12% USD/MXN 18.60 ▲ 0.48% USD/CLP 1,001 ▲ 0.60% USD/COP 3,302 ▼ 0.00% USD/PEN 3.41 ▲ 0.09% USD/ARS 1,546 ▲ 0.15% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 — 0.00% USD/DOP 60.63 ▲ 0.07% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 ▲ 3.24% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.75% USD/TTD 6.75 ▲ 2.58% EUR/BRL 6.31 ▲ 1.04% BRENT 94.43 ▼ 1.47% WTI 87.68 ▼ 0.99% IRON ORE 161.91 — — COPPER 6.05 ▼ 0.52% GOLD 3,874 ▼ 0.32% SILVER 47.30 ▼ 3.54% SOY 1,229 ▼ 1.13% CORN 445.00 ▼ 0.11% WHEAT 590.25 ▼ 0.51% COFFEE 274.75 ▼ 1.40% SUGAR 18.33 ▼ 0.43% ORANGE JUICE 136.85 ▼ 2.91% COTTON 81.51 ▲ 3.47% COCOA 5,254 ▲ 2.64% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00%
since 2009
Monday, November 16, 2026

Brazil Business - Brazil

Brazil’s Eurofarma Teams With Japan’s Eisai to Bring the Insomnia Drug Dayvigo to Market

By · · 5 min read
Eurofarma Eisai insomnia drug Dayvigo - white pills and tablets on a plate
Illustrative photo of medicine pills. Brazil’s Eurofarma has partnered with Japan’s Eisai to bring the insomnia drug lemborexant (Dayvigo) to Brazil. (Photo: epSos.de, CC BY 2.0, Wikimedia Commons.)

Brazil · Business

Key Facts

  • —What happened Brazil’s Eurofarma will sell Japan’s Eisai insomnia drug Dayvigo in a new partnership.
  • —How big a jump The target market is worth about US$240 million a year in Brazil.
  • —The catch The drug is approved but cannot be sold until Brazil’s CMED board sets a maximum price.
  • —What it means Dayvigo blocks a wake chemical, unlike older sedatives that broadly dull the brain.
  • —Who it touches Eurofarma, based in São Paulo, will push the pill through its Latin American pharmacy network.
  • —What comes next A launch date is unnamed and depends on the pending CMED price ceiling.

The deal pairs Japan’s newest sleep science with Brazil’s biggest homegrown drug sales force. Aimed at a market worth about US$240 million a year.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

Brazil’s Eurofarma has struck a partnership with Japan’s Eisai to bring a new insomnia drug to the country’s pharmacies. The medicine is lemborexant, sold under the brand Dayvigo, a sleeping pill that works in a fresh way.

Business daily Valor Econômico reported the deal on 17 August 2026.

What Eurofarma and Eisai Agreed

Eurofarma said it closed a partnership with Eisai to sell Dayvigo in Brazil. The Japanese firm developed the drug, while the Brazilian company brings the local reach.

In short, Eisai supplies the science and Eurofarma supplies the sales muscle. That division of labour matches how the two firms have worked before.

The companies have not spelled out the fine print in public. As a result, the exact shape of the deal, and any money changing hands, remains undisclosed.

How Dayvigo Works

Dayvigo is the brand name for lemborexant, a molecule that targets the brain’s wake system. It blocks orexin, a chemical that keeps people alert.

Because it quiets the signal that keeps you up, sleep is meant to follow more naturally. That is a different route from most pills on the shelf today.

Why the New Mechanism Matters

Older sleeping pills, such as benzodiazepines and so-called Z-drugs, work by broadly sedating the brain. However, they can bring dependence and grogginess.

Lemborexant instead switches off a single wake pathway. For that reason, doctors expect less dependence and fewer hangover effects, though real-world use will tell.

The drug even drew notice abroad for its design. Still, no medicine is risk-free, and patients need a doctor’s guidance.

Where the Drug Stands With Regulators

This is not a plan for some distant approval. Anvisa, Brazil’s health regulator, has already registered Dayvigo for sale.

Even so, the pill is not on pharmacy shelves yet. Before it sells, Brazil’s CMED price board must set a maximum price.

Neither company has named a launch date. Therefore, the timing of the first sale still depends on that pricing step.

A spokesperson for Eurofarma’s press office told The Rio Times the company expects Dayvigo to reach consumers at a price of around R$200 (about US$38). That figure has not been officially confirmed: the final price still depends on the pending ceiling to be set by Brazil’s CMED price board.

The Brazilian Market Eurofarma Is Chasing

Sleepless nights are big business in Brazil. The country’s insomnia-treatment market moves about R$1.3 billion, roughly US$240 million, each year.

That figure explains the appeal of a fresh product. Because demand is steady and large, a novel pill can carve out real share.

Insomnia is also widespread and often untreated. As a result, both firms see room to grow the category, not just split it.

Who Eurofarma Is

Eurofarma is based in São Paulo and ranks among Brazil’s largest homegrown drugmakers. It also sells across much of Latin America.

That footprint is exactly what a foreign partner wants. In short, Eurofarma can push a drug through Brazil’s crowded pharmacy network fast.

The company has long paired local reach with outside science. Meanwhile, it keeps building its own pipeline at home.

Who Eisai Is

Eisai is a Japanese pharmaceutical company headquartered in Tokyo. It researches and develops medicines and sells them worldwide.

The firm is best known lately for Leqembi, an Alzheimer’s treatment it developed with a partner. Lemborexant is another of its in-house discoveries.

Japan’s drugmakers often lean on local partners abroad. For example, Eisai has used exactly this model in Brazil before.

A Partnership With History

This is not the first Eurofarma deal for Eisai. Back in 2018, the two teamed up on the anti-obesity drug lorcaserin.

In that case, Eisai granted Eurofarma exclusive marketing rights in Brazil and in 17 other Latin American markets. The firms also worked together earlier on a cancer treatment.

So the insomnia deal builds on a familiar template. Because the relationship is established, adding a new drug is a smaller leap.

What Is Still Unclear

The public report is thin on terms. It confirms the partnership and the market size, but little else.

It does not say whether the deal is exclusive, nor how the two firms split the work. Any financial figures stay private for now.

The scope also reads as Brazil-focused. However, the companies have not ruled out a wider regional push later.

What Comes Next

The next milestone is a price. Once CMED sets the ceiling, Eurofarma can schedule a launch.

After that, the test is uptake. Because patients and doctors are cautious with new sleep drugs, adoption may build slowly.

For now, though, the headline is simple. A modern insomnia pill is heading toward Brazilian pharmacies, backed by a proven local partner.

Frequently Asked Questions

What did Eurofarma and Eisai agree to do?

Eurofarma partnered with Japan’s Eisai to bring the insomnia drug lemborexant, sold as Dayvigo, to Brazil. Eisai developed it; Eurofarma handles local sales.

How is Dayvigo different from other sleeping pills?

Dayvigo, or lemborexant, blocks orexin, a chemical that keeps the brain awake. Older pills broadly sedate the brain, which can cause more dependence.

Is the drug already for sale in Brazil?

Not yet. Anvisa has registered Dayvigo, but a launch waits on Brazil’s CMED price board setting a maximum price.

How big is Brazil’s insomnia market?

Brazil’s insomnia-treatment market moves about R$1.3 billion, roughly US$240 million, a year, according to Valor Econômico.

Connected Coverage

Sources: Valor Econômico; O Globo; Eisai; Anvisa; The Pharma Letter.

RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.